Business Context and Reporting Period
This Form 6-K filing by AC Immune SA covers the month of December 2023. The registrant is a foreign private issuer based in Lausanne, Switzerland, focused on developing treatments for neurodegenerative diseases.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
The primary material change disclosed is a significant update to the executive leadership team effective January 1, 2024:
- Chief Scientific Officer: Dr. Madiha Derouazi has been appointed to succeed Dr. Marie Kosco-Vilbois, who is retiring.
- Chief Financial Officer: Christopher Roberts has been promoted from Interim Chief Financial Officer to Chief Financial Officer.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, risk factors, contingencies, or unusual items. The document serves solely to announce the personnel changes and incorporates the attached press release by reference into existing registration statements.
Key Facts for Investor Verification
- Verify the effective date of the new executive appointments (January 1, 2024).
- Confirm the retirement status of the former Chief Scientific Officer, Dr. Marie Kosco-Vilbois.
- Review the attached Exhibit 99.1 (Press Release) for additional biographical details on the new appointees.